

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

This announcement is not, and does not form any part of, an offer or invitation for the sale of securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered, sold or otherwise transferred within the United States absent registration or an exemption from registration requirement. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and will contain detailed information about the Company and management, as well as financial statements. The Company does not intend to register any part of the offering in the United States.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

REDEMPTION OF U.S.\$300,000,000 1.50 PER CENT.

CONVERTIBLE BONDS DUE 2024

(ISIN: XS2019971279; Common Code: 201997127; Stock code: 5993)

References are made to (i) the announcements of Luye Pharma Group Ltd. (the “**Company**”) dated 24 June 2019, 9 July 2019, 5 September 2019 and 29 June 2020 (collectively, the “**Announcements**”); and (ii) the offering circular dated 4 July 2019 (the “**Offering Circular**”) in relation to the U.S.\$300,000,000 1.50 per cent. convertible bonds due 2024 issued by the Company (the “**Bonds**”).

Unless the context requires otherwise, terms which are undefined herein shall bear the same meaning as those defined in the Announcements and the Offering Circular.

Pursuant to Condition 8(E) of the Terms and Conditions of the Bonds, the Company has received Optional Put Exercise Notices in respect of U.S.\$291,611,000 in principal amount of the Bonds requiring the Company to redeem such Bonds at 107.07 per cent. of their principal amount on 9 July 2022. As at the date of this announcement, the Company has settled the amount payable for the repurchase of the Bonds.

All Bonds redeemed as provided in Condition 8(E) above will forthwith be cancelled and such Bonds may not be reissued or resold. After the cancellation, no Bonds will remain outstanding. The Company will apply to the Hong Kong Stock Exchange for the delisting of the Bonds following the cancellation.

By Order of the Board of
LUYE PHARMA GROUP LTD.
LIU Dian Bo
Chairman

Hong Kong, 11 July 2022

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. SUN Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.